Spyre Therapeutics
SYRE
78 hedge funds and large institutions have $286M invested in Spyre Therapeutics in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 29 increasing their positions, 26 reducing their positions, and 9 closing their positions.
204% more call options, than puts
Call options by funds: $316K | Put options by funds: $104K
12% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.11% less ownership
Funds ownership: 3.46% → 3.35% (-0.11%)
7% less funds holding
Funds holding: 84 → 78 (-6)
13% less capital invested
Capital invested by funds: $328M → $286M (-$42.8M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$5.28M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.89M |
| 3 |
ACM
Altium Capital Management
New York
|
+$2.49M |
| 4 |
Millennium Management
New York
|
+$1.25M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$976K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.49M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$3.92M |
| 3 |
BlackRock
New York
|
-$1.79M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.39M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$946K |
SYRE Hedge Fund Activity: Q2 2021 in Review
78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2021, worth a combined $286M — down 13% from $328M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SYRE and 3 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 29 added.
The largest buyer was Suvretta Capital Management, adding an estimated $5.28M. The largest seller was Point72 Asset Management, cutting an estimated $7.49M.
- 78 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2021, down from 84 in Q1 2021.
- Funds reported $286M of Spyre Therapeutics stock for Q2 2021, down 13% quarter-over-quarter.
- 3 funds opened new Spyre Therapeutics positions in Q2 2021 and 9 closed out, a net change of -6 holders.
- The largest Spyre Therapeutics buyer in Q2 2021 was Suvretta Capital Management, an estimated $5.28M added.
- The largest Spyre Therapeutics seller in Q2 2021 was Point72 Asset Management, an estimated $7.49M sold.
Based on aggregated 13F filings for Q2 2021.